Pulmonary Arterial Hypertension (PAH)
Cardiovascular
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
RegeneronREGN13335
Inhibikase TherapeuticsIkT-001Pro
35PharmaHS135
Clinical Trials (3)
Total enrollment: 104 patients across 3 trials
Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Start: Jan 2026Est. completion: Aug 202899 patients
Phase 2Not Yet Recruiting
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
Start: Jun 2025Est. completion: Jun 2027
Phase 2Withdrawn
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
Start: Oct 2024Est. completion: Mar 20255 patients
Phase 1Terminated
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr
Clinical Consultant
Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago
Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology
Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr
Trainee Technical Specialist
Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago
Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90
Johnson & Johnson
Issy-les-Moulineaux, France
20h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space